VX-659 + Tezacaftor + Ivacaftor - A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Veterans Administration New Jersey Health Care System East Orange, NJ, NJ USA
tshalad@ohsu.edu.test